BR100 Decreased By (-0.98%)
BR30 Decreased By (-0.58%)
KSE100 Decreased By (-0.97%)
KSE30 Decreased By (-1.07%)
AGHA 7.70 Decreased By ▼ -0.11 (-1.41%)
BECO 5.13 Decreased By ▼ -0.08 (-1.54%)
BML 56.67 Decreased By ▼ -0.83 (-1.44%)
BOP 33.75 Decreased By ▼ -0.28 (-0.82%)
CNERGY 9.88 Decreased By ▼ -0.08 (-0.8%)
CSIL 5.29 Decreased By ▼ -0.02 (-0.38%)
FCCL 53.09 Decreased By ▼ -1.61 (-2.94%)
FFL 16.52 Decreased By ▼ -0.17 (-1.02%)
FNEL 1.21 Decreased By ▼ -0.02 (-1.63%)
KEL 7.22 Decreased By ▼ -0.18 (-2.43%)
KOSM 5.72 Decreased By ▼ -0.05 (-0.87%)
LOTCHEM 29.31 Decreased By ▼ -0.01 (-0.03%)
MLCF 92.16 Decreased By ▼ -2.20 (-2.33%)
NBP 201.61 Decreased By ▼ -1.44 (-0.71%)
NCPL 56.45 Decreased By ▼ -0.55 (-0.96%)
NPL 66.57 Decreased By ▼ -1.13 (-1.67%)
OGDC 316.29 Increased By ▲ 0.45 (0.14%)
PACE 10.48 Decreased By ▼ -0.16 (-1.5%)
PAEL 42.04 Decreased By ▼ -1.16 (-2.69%)
PIBTL 16.41 Decreased By ▼ -0.33 (-1.97%)
PPL 216.84 Decreased By ▼ -2.94 (-1.34%)
PRL 50.86 Increased By ▲ 1.67 (3.39%)
PTC 69.86 Decreased By ▼ -0.67 (-0.95%)
SSGC 26.98 Decreased By ▼ -1.27 (-4.5%)
TBL 9.73 Decreased By ▼ -0.13 (-1.32%)
TELE 8.65 Decreased By ▼ -0.14 (-1.59%)
TPL 17.90 Decreased By ▼ -0.34 (-1.86%)
TPLP 13.39 Increased By ▲ 0.12 (0.9%)
TREET 22.56 Decreased By ▼ -0.16 (-0.7%)
TRG 59.26 Decreased By ▼ -0.88 (-1.46%)
By

NEW YORK: The US Food and Drug Administration on Monday authorized the use of a third dose of the Pfizer and BioNTech Covid-19 vaccine for children aged between 12 and 15 years, and narrowed the time for all booster shots to 5 months from 6 months after primary doses.

The agency also authorized a third shot in children aged 5 through 11 years who are immunocompromised. The FDA said it reviewed published data and real world evidence on the safety of booster doses provided by the Israeli Ministry of Health including data from over 6,300 individuals 12-to-15 years of age who received a Pfizer shot.

Global COVID-19 cases are surging due to the Omicron variant and health authorities have warned that its extremely high transmissibility could overwhelm many health systems. Laboratory tests have shown that two doses of the Pfizer-BioNTech and Moderna vaccines generate low immune responses against Omicron, while boosters appear to be protective against the highly-mutated variant.

Comments

Comments are closed for this article.